Welcome To Mast Therapeutics, Inc.

We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from
over two decades of clinical, nonclinical and manufacturing experience with purified and non-
purified poloxamers, to develop vepoloxamer, our lead product candidate, for serious or life-
threatening diseases with significant unmet needs.


      >> Read the latest CEO Blog entry


Click here to view our latest press releases, SEC filings, and information about company events, media, and analyst coverage. read more


Click here to learn more about our lead product candidate, vepoloxamer.
  read more

Clinical Trials

We have initiated a Phase 3 clinical study of vepoloxamer for the treatment of sickle cell disease. Click here for more info. read more